Intermittent, luteal phase nefazodone treatment of premenstrual dysphoric disorder

A. Kodesh, S. Katz, A. G. Lerner, B. Finkel, M. Sigal

Research output: Contribution to journalArticlepeer-review


Three outpatients who fulfilled full DSM-IV diagnostic criteria for premenstrual dysphoric disorder (PDD) were successfully treated with intermittent (luteal phase) nefazodone. They received the medication at low doses of up to 100 mg/day (50 mg b.i.d.), for 2 weeks through the luteal phase of the menstrual cycle only. All the patients reported a marked symptomatic improvement, including full remission of their emotional symptoms, and two achieved in addition full remission of their somatic symptoms. Side-effects reported during the treatment were mild. The use of luteal phase nefazodone seems to be a promising treatment strategy for the management of PDD. It offers advantages over daily dosing throughout the menstrual cycle, such as reduced incidence and severity of side-effects, and avoids the stigma that may accompany the continuous use of psychopharmacological treatment, with the advantage that compliance may be improved.

Original languageEnglish
Pages (from-to)58-60
Number of pages3
JournalJournal of Psychopharmacology
Issue number1
StatePublished - Jan 2001
Externally publishedYes


  • Nefazodone
  • Premenstrual dysphoric disorder
  • Serotonin

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Pharmacology


Dive into the research topics of 'Intermittent, luteal phase nefazodone treatment of premenstrual dysphoric disorder'. Together they form a unique fingerprint.

Cite this